

## CLINICAL VIGNETTE

---

### A Male Patient with BRCA2 Positivity

---

Peter Lefevre, MD

A 42-year-old male presents for his annual wellness visit. He is in good health, with no significant prior medical history and is taking no prescription medications. His sister was recently diagnosed with breast cancer at age 47. Because his mother also had breast cancer, his sister was tested and found to be a carrier of the *BRCA2* gene. Otherwise, his family history is also significant for pancreatic cancer in his maternal grandfather and colon cancer in his maternal grandmother.

The patient was also tested for the *BRCA2* mutation and found to be positive. He inquires about the impact this mutation will have on his overall health and what type of screening tests he should undergo at this point.

An asymptomatic male with *BRCA2* mutation positivity has increased risk of breast and prostate cancer. Additionally, his family history of pancreatic cancer in the setting of *BRCA* positivity means that the patient also has an increased risk of pancreas cancer.<sup>1</sup> Increased incidence of melanoma, colorectal cancer, stomach and biliary cancers has also been reported, but the associations have yet to be replicated. Thus, the efficacy of screening (or accelerated screening) for these tumors is not yet known.

The prostate cancer risk in a male with *BRCA2* positivity has been reported to be as high as 33% by the age of 65.<sup>2</sup> Studies have also reported more aggressive prostate cancer in *BRCA2* carriers than the general population.<sup>3</sup> Thus, it has been recommended that prostate cancer screening with serum prostate specific antigen, PSA tests should begin at age 40 and continue annually.<sup>4</sup>

Breast cancer risk is also increased in males who carry either the *BRCA1* or *BRCA2* gene mutation. There is a lifetime risk of 1% among those with the *BRCA1* mutation and a 6% risk among those with the *BRCA2* mutation. Therefore, breast cancer surveillance should be performed, with monthly self-exams and annual clinical exams starting at age 35. The utility of annual screening mammogram or ultrasound imaging in this population has not been shown among men with normal clinical exams.<sup>5</sup>

Regarding pancreatic cancer surveillance, the recommendation is to follow the International Cancer of the Pancreas Screening Consortium guidelines.<sup>6</sup> These consider both family history as well as known genetic syndromes. When screening is appropriate, annual endoscopic ultrasound and/or magnetic resonance

cholangiopancreatography (MRCP) is recommended. For this recommendation, patients need to have a first degree relative with pancreatic cancer, in addition to *BRCA* positivity, to warrant testing.

Lastly, colorectal cancer screening should follow the same guidelines as those of the general population, taking into account family history. Melanoma screening with annual skin surveys is generally recommended, despite the lack of definitive evidence associating *BRCA* and melanoma.

This case presents a number of questions regarding how to manage a patient with a known familial genetic mutation syndrome. As genetic testing becomes more commonplace both in the traditional clinical and the commercial arenas, primary care physicians will frequently be the first point of contact for patients with newly diagnosed genetic syndromes. With the development of new tests and recommendations, it is important that primary physicians maintain current knowledge of this field.

#### REFERENCES

1. **Thompson D, Easton DF; Breast Cancer Linkage Consortium.** Cancer Incidence in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2002 Sep 18;94(18):1358-65. PubMed PMID: 12237281.
2. **Breast Cancer Linkage Consortium.** Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst.* 1999 Aug 4;91(15):1310-6. PubMed PMID: 10433620.
3. **Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Oshter PJ, Salinas M, Eccles D, Axcrone K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y, Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeny L; IMPACT Study Collabora-**

tors, Easton DF, Eeles RA. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU Int.* 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14. PubMed PMID: 20840664; PubMed Central PMCID: PMC6057750.

4. **Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.** Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *J Clin Oncol.* 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review. PubMed PMID: 29236593; PubMed Central PMCID: PMC6075860.
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-risk Assessment: Breast and Ovarian. Version 2.2019. [www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_screening.pdf](http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf) (Accessed on September 10, 2018).
6. **Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium.** International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut.* 2013 Mar;62(3):339-47. doi: 10.1136/gutjnl-2012-303108. Epub 2012 Nov 7. Erratum in: *Gut.* 2014 Dec;63(12):1978. Hammell, Pascal [corrected to Hammel, Pascal]. *Gut.* 2014 Jan;63(1):178. Hamell, Pascal [corrected to Hammell, Pascal]. PubMed PMID: 23135763; PubMed Central PMCID: PMC3585492.